Drug Trial Radar · NCT00908596
Primovist / Eovist in Renally Impaired Patients
Last checked: Nov 20, 2026Latest source record: Jul 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
357
Actual
Start
May 2009
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- May 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Primovist/Eovist, will be asked to participate. The administration of contrast agents that contain gadolinium such as Primovist/Eovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in patients with renal impairment. This study is to assess the potential risk to develop NSF in patients with renal impairment after the administration of Primovist/Eovist. Patients who are enrolled in this study will receive a Primovist/Eovist enhanced MRI scan which was prescribed by the referring doctor. After the MRI scan the patient will be included in a two year follow-up period to assess if signs or symptoms suggestive of NSF have appeared.
Conditions
- Contrast Media
Interventions
Gadoxetic acid disodium (Primovist, BAY86-4873)Drug
Primovist/Eovist in approved indications at approved dosages
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and Histopathological InformationTime frame: Up to 24 months following the administration of Primovist/Eovist
Locations
47 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Jacksonville, Florida
Site not named
Honolulu, Hawaii
Site not named
Topeka, Kansas
Site not named
Baltimore, Maryland
Site not named
Ann Arbor, Michigan
Site not named
Brooklyn, New York
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Memphis, Tennessee
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Westmead NSW, Australia
Site not named
Herston, Queensland, Australia
Site not named
Woollongabba, Queensland, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Geelong, Victoria, Australia
Site not named
Graz, Austria
Site not named
Vienna, Austria
Site not named
Heidelberg, Baden-Wurttemberg, Germany
Site not named
Stuttgart, Baden-Wurttemberg, Germany
Site not named
Erlangen, Bavaria, Germany
Site not named
Frankfurt am Main, Hesse, Germany
Site not named
Marburg, Hesse, Germany
Site not named
Hanover, Lower Saxony, Germany
Site not named
Dortmund, North Rhine-Westphalia, Germany
Site not named
Essen, North Rhine-Westphalia, Germany
Site not named
Dresden, Saxony, Germany
Site not named
Magdeburg, Saxony-Anhalt, Germany
Site not named
Berlin, State of Berlin, Germany
Site not named
Gera, Thuringia, Germany
Site not named
Brescia, Italy
Site not named
Milan, Italy
Site not named
Naples, Italy
Site not named
Palermo, Italy
Site not named
Pisa, Italy
Site not named
Rozzano, Milano, Italy
Site not named
Pozzuoli, Napoli, Italy
Site not named
Candiolo, Torino, Italy
Site not named
Seoul, South Korea
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.